Clinic
Legacy Emanuel Hospital & Health Center
Legacy Emanuel Hospital & Health Center was paid $64.24M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoLEGACY EMANUEL HOSPITAL & HEALTH CENTER
PORTLAND, OR 97227
PORTLAND, OR 97227
33aNPI1831112358assigned 07/25/2006
33bProvider typePhysical Therapy Clinic/Center
28Total paid$64.24M
24GClaims677,162
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Therapy Clinic/Center providers in Oregon
Rank by total paid#1 of 44
Median peer was paid$81K
This provider vs. median794×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JENSEN, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,452 | $8.61M | |
| 2019 | 94,060 | $8.34M | |
| 2020 | 74,837 | $6.96M | |
| 2021 | 84,423 | $7.74M | |
| 2022 | 111,725 | $10.52M | |
| 2023 | 111,053 | $11.38M | |
| 2024incomplete | 96,612 | $10.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 102,910 | 96,224 | $18.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 63,821 | 59,419 | $16.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 47,137 | 43,288 | $15.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 14,620 | 13,870 | $1.69M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 15,338 | 14,265 | $1.63M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.5% | 19,063 | 9,514 | $1.62M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 7,099 | 5,663 | $1.32M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 15,392 | 7,555 | $906K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 19,001 | 11,922 | $841K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,801 | 3,457 | $552K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 7,606 | 6,453 | $458K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,071 | 3,940 | $418K |
171 more codes
| 92587 | <1% | 2,142 | $395K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,942 | $349K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,046 | $297K |
| 92523 | <1% | 1,390 | $240K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,521 | $174K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,553 | $170K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,643 | $151K |
| G0378 | Hospital observation service, per hour | <1% | 3,799 | $149K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,083 | $140K |
| 97597 | <1% | 1,661 | $121K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,073 | $114K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 23,345 | $112K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 328 | $97K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,187 | $91K |
| 92609 | <1% | 1,062 | $77K | |
| 97166 | <1% | 933 | $69K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,233 | $67K |
| 97161 | <1% | 867 | $65K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 159 | $63K |
| 92567 | <1% | 3,107 | $60K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,701 | $59K |
| 80053 | Comprehensive metabolic panel | <1% | 52,817 | $53K |
| 97802 | <1% | 842 | $51K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 189 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,775 | $46K |
| 76770 | <1% | 433 | $46K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 256 | $46K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 526 | $40K |
| 92610 | <1% | 603 | $39K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 361 | $39K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 41 | $39K |
| 29581 | <1% | 378 | $35K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 226 | $34K |
| S9981 | Medical records copying fee, administrative | <1% | 1,816 | $31K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 52 | $31K |
| 97162 | <1% | 339 | $24K | |
| 92579 | <1% | 400 | $20K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 171 | $19K |
| D1120 | Dental cleaning, child | <1% | 53 | $16K |
| 97803 | <1% | 225 | $14K | |
| 54640 | <1% | 13 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 68,557 | $13K |
| 74018 | <1% | 1,013 | $13K | |
| D1206 | Topical application of fluoride varnish | <1% | 92 | $12K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 38 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,511 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,036 | $11K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 39 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,273 | $11K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 102 | $10K |
| 87631 | <1% | 1,189 | $9K | |
| 90686 | <1% | 393 | $7K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 26 | $7K |
| 29580 | <1% | 169 | $7K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 114 | $6K |
| 95951 | <1% | 17 | $5K | |
| 92582 | <1% | 73 | $5K | |
| 92555 | <1% | 120 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,360 | $5K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 43 | $5K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 199 | $4K |
| 84484 | <1% | 10,499 | $4K | |
| 92526 | <1% | 73 | $4K | |
| S9982 | Medical records copying fee, per page | <1% | 1,555 | $4K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 27 | $4K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 25 | $4K |
| 84703 | <1% | 8,453 | $3K | |
| 96376 | <1% | 1,169 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,209 | $3K |
| 93308 | <1% | 153 | $3K | |
| 92083 | <1% | 60 | $3K | |
| 87040 | <1% | 413 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 736 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 50 | $2K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 208 | $2K |
| 92551 | <1% | 162 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $2K |
| D9420 | <1% | 14 | $2K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 12 | $1K |
| 81001 | <1% | 4,384 | $1K | |
| 36592 | <1% | 27 | $1K | |
| 92586 | <1% | 12 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,167 | $1K |
| 83690 | <1% | 4,880 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,055 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,783 | $951.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,852 | $780.57 |
| J3490 | Unclassified drugs | <1% | 239 | $769.16 |
| 97165 | <1% | 12 | $733.23 | |
| 90670 | <1% | 32 | $702.72 | |
| 97763 | <1% | 22 | $700.59 | |
| 82803 | <1% | 115 | $689.21 | |
| 86140 | <1% | 2,223 | $681.08 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 29 | $672.43 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,709 | $662.77 |
| 81003 | <1% | 4,389 | $651.87 | |
| 83735 | <1% | 1,330 | $624.53 | |
| 82077 | <1% | 1,011 | $615.67 | |
| 93321 | <1% | 151 | $610.02 | |
| 93976 | <1% | 14 | $603.98 | |
| 90723 | <1% | 27 | $592.92 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,247 | $583.28 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 259 | $578.63 |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 13 | $548.43 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $491.27 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 626 | $481.30 |
| 85610 | <1% | 1,287 | $446.27 | |
| 97116 | <1% | 16 | $408.11 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,984 | $396.10 |
| 95816 | <1% | 16 | $391.82 | |
| 99173 | <1% | 132 | $387.76 | |
| 86850 | <1% | 713 | $340.58 | |
| 94060 | <1% | 13 | $328.75 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 980 | $322.26 |
| 85027 | <1% | 1,021 | $309.69 | |
| 90647 | <1% | 14 | $307.44 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 24 | $301.60 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,120 | $297.64 |
| 86900 | <1% | 756 | $286.08 | |
| 72020 | <1% | 14 | $281.56 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,334 | $274.01 |
| 82728 | <1% | 286 | $239.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,356 | $239.89 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 145 | $230.26 |
| A9270 | Non-covered item or service | <1% | 1,952 | $225.18 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 776 | $216.00 |
| 99451 | <1% | 14 | $200.00 | |
| D0191 | <1% | 15 | $195.15 | |
| 86901 | <1% | 756 | $166.63 | |
| 85652 | <1% | 891 | $147.61 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $124.41 |
| D0272 | Bitewings - two radiographic images | <1% | 27 | $112.40 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 890 | $94.41 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 502 | $89.15 |
| 96127 | <1% | 14 | $77.70 | |
| 80299 | <1% | 95 | $52.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26 | $49.10 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 215 | $46.15 |
| 96160 | <1% | 12 | $39.96 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 479 | $26.05 |
| 80076 | <1% | 13 | $24.00 | |
| 87077 | <1% | 130 | $23.65 | |
| 0004A | <1% | 22 | $21.90 | |
| 85018 | <1% | 12 | $19.92 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 137 | $13.42 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 634 | $8.00 |
| 83550 | <1% | 58 | $6.11 | |
| 87081 | <1% | 213 | $5.64 | |
| 83540 | <1% | 58 | $4.90 | |
| 87186 | <1% | 69 | $4.36 | |
| 36416 | <1% | 408 | $3.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 65 | $1.16 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 192 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 204 | $0.00 |
| 88304 | 0% | 14 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 98 | $0.00 |
| 88300 | 0% | 103 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 65 | $0.00 |
| A6456 | Zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 350 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 26 | $0.00 |
| D0240 | 0% | 15 | $0.00 | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 0% | 1,758 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 218 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 156 | $0.00 |
| 51701 | 0% | 40 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 111 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 45 | $0.00 |
| 94799 | 0% | 12 | $0.00 | |
| 92133 | 0% | 41 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 29 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJENSEN, SARAH (VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.